The Age of Personalized Medicine: Trends and Opportunities Reflected in the U.S. Experience
17 April 2013
Foley and ChinaBio invite you to join us for our upcoming executive workshop, which will explore this paradigm shift toward personalized medicine and its global implications for China’s life sciences business executives, health care professionals, and academic researchers.
Topics to be discussed include:
- Business and social factors driving the move to personalized medicine, including non-sustainable medical costs, a decline in pharma R&D productivity, and the rise of patient-oriented health care
- Regulatory and intellectual property challenges to formulating a viable business model in the personalized medicine arena
- Potential for strategic collaborations with U.S. companies focused on different aspects of personalized medicine, such as genomic sequencing, biomarker substantiation, genetic testing, and electronic health records
- Post-grant patent issues, reducing patent litigation cost, and other risk management issues in the United States
Confirmed Speakers
- Andrew S. Baluch, Special Counsel, Intellectual Property Department and China Practice, Foley & Lardner LLP
- Nathan A. Beaver, Partner, Life Sciences Industry Team, Foley & Lardner LLP
- Song (Max) Lin, China Associate, Chemical, Biotechnology & Pharmaceutical Practice, Foley & Lardner LLP
- Alex Y. Nie, Associate, Chemical, Biotechnology & Pharmaceutical Practice and Life Sciences Industry Team, Foley & Lardner LLP
- Greg B. Scott, President and Founder, ChinaBio LLC
This workshop is complimentary; however, due to seating limitations, pre-registration is required. An acknowledgement email will be sent upon receipt of your registration request.
For more information, contact Delia Dai at [email protected] or 001.312.832.4506, or Emily Zhang at [email protected] or 86.21.5137.0751, ext. 20.
People
Related Insights
13 September 2024
IP Litigation Current
Federal Circuit Says No Timing Requirement To Qualify As A POSITA
September 24, 2024
Events
Do You Have AI Blind Spots in Your Licensing Agreements? Revisiting the Past, Considering the Present, and Planning for the Future
On Tuesday, September 24, Foley Partner Andrew Gross will speak on the panel “Do You Have AI Blind Spots in Your Licensing Agreements?
12 September 2024
Manufacturing Industry Advisor
Cybersecurity in the Age of Industry 4.0 – Part 1
As the manufacturing sector continues to embrace the hyper-connected era of Smart Manufacturing, known as Industry 4.0, more and more organizations are integrating advanced automation, artificial intelligence, the Internet of Things, and other cutting-edge innovations into their operations.